| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 48 (2022): 726-733 |doi: 10.2306/scienceasia1513-1874.2022.103

pPeOp from Omphalia lapidescens Schroet suppresses the proliferation of cervical cancer HeLa cells via JAK/STAT3 signaling pathway

Yan Chen, Zhenjie Fu, Yuqin Xu, Yitao Chen*, Peilei Pan*

ABSTRACT:      pPeOp is a protein extracted from the sclerotium of Omphalia lapidescens. Several studies have shown its anti-carcinogenic effects. However, its functions in cervical cancer and the underlying cellular mechanisms are relatively unknown. Here, we examined the effect and molecular mechanism of pPeOp on HeLa cells. The MTS assay and EdU assay showed that pPeOp decreased Hela cell viability and proliferation in a dose-dependent manner. Besides, the quantitative real-time PCR (qRT-PCR) and western blot analysis showed that the mRNA levels of JAK1, JAK2, GP130, and STAT3 and protein levels of STAT3 and p-STAT3 were significantly decreased, whereas the mRNA expression levels of SOCS1 and SOCS3 were significantly elevated in HeLa cells. Furthermore, Interleukin-6 (IL-6) and NSC74859 were used as the agonist and inhibitor of the JAK/STAT3 signaling pathway, respectively. The flow cytometry and MTS assay showed that the antitumor effect was increased when pPeOp was co-treated with IL-6, while decreased with inhibitor treatment. These results demonstrate that pPeOp could effectively inhibit the proliferation and viability of cervical cancer cells by regulating JAK/STAT3 signaling pathway, suggesting that pPeOp may serve as a novel therapeutic agent for cervical cancer

Download PDF

46 Downloads 877 Views

a School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053 China

* Corresponding author, E-mail: cytworld@163.com, panplei@163.com

Received 19 Sep 2021, Accepted 5 May 2022